Copyright
©The Author(s) 2016.
World J Hepatol. Jan 8, 2016; 8(1): 58-68
Published online Jan 8, 2016. doi: 10.4254/wjh.v8.i1.58
Published online Jan 8, 2016. doi: 10.4254/wjh.v8.i1.58
Table 1 Isolated biological criteria for the selection of candidates with hepatocellular carcinoma for liver transplantation
Ref. | Pretrasplant AFP levels (ng/mL) | Importance | |
Figueras et al[19] | > 300 | Factor for mortality | |
Yao et al[16] | > 1.000 | Reduced survival | |
Bruix[20] | > 200 | Significant worse outcomes | |
Xu et al[21] | > 400 | Higher tumor recurrence | |
Mailey et al[22] | Low ( ≤ 20) | Mediun and high: Higher mortality | |
Mediun (20-399) | |||
High (≥ 400) | |||
Muscari et al[23] | DFS | Recurrence | |
Normal | 71% | 4% | |
10-150 | 75% | 10% | |
150-500 | 57% | 24% | |
> 500 | 46% | 62% | |
Chiao et al[24] | > 1.000 | Reason for exclusion from the WL | |
Hameed et al[25] | |||
Menon et al[26] | > 10.000 | Reason for exclusion from the WL |
Table 2 Selection criteria base on radiological/morphological tumor characteristics
Ref. | Parameters | Importance |
Bismuth et al[30] | Up to 3 nodules | Best results |
Each < 3 cm | ||
Mazzaferro et al[31] | Single lesion < 5 cm | DFS > 75% |
< 3 lesions, each < 3 cm | Recurrence < 15% | |
No macrovascular invasion | ||
No extrahepatic disease | ||
Löhe et al[34] | Single tumor with size > 5 cm | Reduction in DFS |
Yao et al[16] | Single lesion ≤ 6 cm | DFS > 75% |
2-3 lesions each ≤ 4.5 cm | Recurrence < 15% | |
Total tumor diameter ≤ 8 cm | ||
Mazzaferro[41] | Ordinates: n of tumors | Progressive reduction of 5 yr survival |
Abscissas: Tumor size | ||
Mazzaferro et al[42] | Up to 7, as the sum of: | 71.2% 5 yr survival |
Largest tumor in centimeter and n of tumors | ||
Jang et al[46] | 10 as the sum of: | If >: Decreased DFS |
Largest tumor in cm and | ||
n of tumors |
Table 3 Selection criteria based on functional/radiological features of the tumor
Ref. | Parameters | Importance |
Hiraoka et al[56] | Hyperintensity on gadoxetic acid-enhanced MRI | HCC with more malignant potential |
Ferda et al[12] | Hipervascularity or hiperaccumulation of (18)FDG/PET/with Dual-phase CT angiography (arterial/portal phase) | Distinguishing between welland |
Poorly differentiated HCC | ||
Ochi et al[57] | High positivity in (18)FDG/PET/CT | Increase the risk of early recurrence |
Kornberg et al[58] | mSUV | Reflects the existence of distant microsatellite |
Kornberg[59] | Positivity in (18)FDG/PET/CT | Statistically significant lower survival post LT |
Table 4 Combined morphological/biological selection criteria
Ref. | Parameters | Importance |
DuBay et al[60] | Liver tumor biopsy | Excluding poorly differentiated tumors |
Toso et al[52] | TTV > 115 cm3 | Reduced survival at 3 yr (< 50%) |
AFP > 400 ng/mL | Limit for indication for LT | |
Lai et al[62] | AFP > 400 ng/mL | Strongest predictor for recurrence |
Total tumor diameter > 8 cm | ||
Duvoux et al[63] | Model combining log10 AFP, tumor size and n of tumors: Score > or < 2 | Score greater that 2 predict a market increase in 5 yr risk of recurrence and decreased survival |
Berry et al[66] | AFP < 15 or > 15 ng/mL | AFP levels predicts post-transplant survival independently of MC |
Table 5 Japanese combined morphological/biological selection criteria for living-donor liver transplant
Ref. | Parameters | Importance: Limits for LDLT | ||||
Value | 1p | 2p | 3p | 4p | ||
Yang et al[67] | T size (cm) | ≤ 3 | 3.1-5 | 5.1-6.5 | > 6.5 | Patients with 3-6 points are transplantable |
of tumors | 1 | 2-3 | 4-5 | > 5 or 6 | Those with 7-12 points are not transplantable | |
AFP (ng/mL) | < 20 | 20-200 | 200.1-1.000 | < 1.000 | ||
Akamatsu et al[68] | Up to 5 nodules | Upper limit for LDLT | ||||
Maximum diameter ≤ 5 | ||||||
Kaido et al[69] | Less that 10 nodules, all < 5 cm | Upper limit for LDLT | ||||
DCP < 400 mAu/mL | ||||||
Shirabe et al[70] | n of nodules: No limit | Upper limit for LDLT | ||||
Maximun diameter: < 5 cm | ||||||
DCP < 300 mAu/mL |
- Citation: Soriano A, Varona A, Gianchandani R, Moneva ME, Arranz J, Gonzalez A, Barrera M. Selection of patients with hepatocellular carcinoma for liver transplantation: Past and future. World J Hepatol 2016; 8(1): 58-68
- URL: https://www.wjgnet.com/1948-5182/full/v8/i1/58.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i1.58